Conference Coverage: ASH 2022 – Focus on Lymphoma
Lymphoma-specific discussions on latest research updates, therapeutic advances, and their application in clinical decision-making.
December 16, 2022
FACULTY CHAIR
Brad S. Kahl, MD
Washington University School of Medicine, St Louis, MO, USA
Faculty Members
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland, OH, USA
Martin Dreyling, MD, PhD
University of Munich Hospital, Großhadern, Germany
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci (UK)
Cancer Research UK Barts Centre, London, UK
Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany
Jasmine Zain, MD
City of Hope, Duarte, CA, USA
REPORT SNAPSHOT
- Advances in DLBCL/Aggressive B-Cell Lymphoma
- Advances in Indolent Lymphomas (FL and MZL)
- Advances in MCL
- Advances in T-Cell Lymphoma
- Evolving Use of BTK Inhibitors in CLL
- Role of Fixed-Duration and MRD-Guided Strategies in CLL
